Detailed analysis of the “Myocardial Infarction-Pipeline Review, H1 2017” helps to understand the various types of Continuous Positive Airway Pressure (CPAP) Machine products that are currently in use, along with the variants that would gain prominence in the future.
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction – Pipeline Review, H1 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.
Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).
Key Companies Mentioned:
Amarantus Bioscience Holdings Inc, AstraZeneca Plc, Athersys Inc, Bayer AG, Bharat Biotech International Ltd, BioCardia Inc, Biscayne Pharmaceuticals Inc, Capricor Therapeutics Inc, CellProthera, Chrysalis BioTherapeutics Inc, Compugen Ltd, Cynata Therapeutics Limited, Diffusion Pharmaceuticals Inc, FibroGen Inc, Hemostemix Ltd, Human Stem Cells Institute, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Inotrem SA, Juventas Therapeutics Inc, Laboratoires Pierre Fabre SA, Lee’s Pharmaceutical Holdings Ltd, LG Chem, Ltd., Medestea Research & Production SpA, Mesoblast Ltd, Moderna Therapeutics Inc, Navya Biologicals Pvt Ltd, New World Laboratories Inc, Novartis AG, NuvOx Pharma LLC, Omeros Corp, Opsona Therapeutics Ltd, Otsuka Holdings Co Ltd, Pharmahungary Group, Primary Peptides Inc, Quark Pharmaceuticals Inc, Recardio GmbH, RegeneRx Biopharmaceuticals Inc, Reliance Life Sciences Pvt Ltd, Rubicon Biotechnology Inc, Serodus ASA, Silver Creek Pharmaceuticals Inc, Stemedica Cell Technologies Inc, TaiGen Biotechnology Co Ltd, Targazyme Inc, Tasly Pharmaceutical Group Co Ltd, The International Biotechnology Center (IBC) Generium, TiGenix NV, Vicore Pharma AB, XBiotech Inc, Yuyu Pharma Inc and Zydus Cadila Healthcare Ltd.
Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/247008 . AND if you have enquire before buying this report visit at http://www.orbisresearch.com/contacts/enquiry-before-buying/247008 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Browse this full report @ http://www.orbisresearch.com/reports/index/myocardial-infarction-pipeline-review-h1-2017 .
The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 14, 9, 37, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 20 and 7 molecules, respectively.
Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample for this report @ http://www.orbisresearch.com/contacts/request-sample/247008 .
The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Figures
Number of Products under Development for Myocardial Infarction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: firstname.lastname@example.org
Follow Us on Linkedin: https://www.linkedin.com/company/orbis-research